Health alert over diabetes drug linked to heart risks - Guardian
Extract:
"A review of the safety of a diabetes drug used by millions of patients was launched in America last night after a study linked it to an increased risk of heart attacks.
Patients using Avandia, the brand name given by GlaxoSmithKline to rosiglitazone, ran a 45% higher risk of a heart attack than those using a placebo or alternative treatment, according to the results of the study published in a leading medical journal.
The US regulator the food and drug administration (FDA) responded by issuing a formal alert to doctors. And congressional leaders in Washington announced that the House oversight committee would hold hearings on GSK's handling of the drug next month.
GSK, the UK's leading pharmaceutical company, disputed the study's findings, arguing it was based on "incomplete evidence and a methodology that the author admits has significant limitations".
Avandia has been taken by more than 6 million people worldwide since it was licensed eight years ago. The drug is one of a group that lower blood glucose levels for people with type 2 diabetes - the late onset form of the disease which is linked to obesity. The FDA warned doctors to be aware of the study published online by the New England Journal of Medicine linking it to heart disease. "
Pharmaceuticals usually carry risks...)o: - You can reduce your risk of developing type 2 diabetes by eating less salt/sodium. And if you already have type 2 diabetes, you can improve your condition by eating less salt/sodium.
Lose weight by eating less salt! Go on! - Try it! - You will feel so much better!
See my website www.wildeaboutsteroids.co.uk
(The site does not sell anything and has no banners or sponsors or adverts - just helpful information.)
Tuesday, May 22, 2007
Avandia is suspected of increasing risk of heart attacks.
Posted by Willow at 4:16 pm
Labels: Avandia, GlaxoSmithKline, heart attack, Lose weight, Obesity, Pharmaceuticals, rosiglitazone, sodium intake, The Guardian, Type 2 Diabetes
Subscribe to: